Is oral lipid-based delivery for drug targeting to the brain feasible?

Brookes, Alice; Ji, Liuhang; Bradshaw, Tracey D.; Stocks, Michael; Gray, David; Butler, James; Gershkovich, Pavel

Abstract

This review outlines the feasibility of oral lipid-based targeted delivery of drugs to the brain, including permeation of the central nervous system's (CNS) protective blood–brain barrier (BBB). The structure of the BBB and disruption caused by varying disease states highlights the need for disease-specific approaches to alter permeation. Disruption during disease state, and the effects of certain molecules on the barrier, demonstrate the possibility of exploiting such BBB disruption for drug delivery. Many administration methods can be used to target the brain, but oral administration is considered ideal for chronic, long-term illnesses. Several lipids that have been shown to facilitate drug delivery into the brain after systemic administration, but could also be delivered orally, are discussed, including oleic acid, triolein, alkylglycerol, and conjugates of linoleic and myristic acids. Current data reveal the potential for the use of such lipids as part of oral formulations for delivery to the brain by reaching sufficient plasma levels after administration to increase the permeability of the BBB. However, gaps in the literature remain regarding the concentrations and form of most lipids required to produce the desired effects. The use of lipids via oral delivery for brain targeting has not been investigated thoroughly enough to determine with certainty if similar permeability-enhancing effects would be observed as for parenteral administration. In conclusion, further research to fill research gaps is needed, but the limited evidence suggests that oral lipid-based drug delivery for brain targeting is potentially feasible.

Citation

Brookes, A., Ji, L., Bradshaw, T. D., Stocks, M., Gray, D., Butler, J., & Gershkovich, P. (2022). Is oral lipid-based delivery for drug targeting to the brain feasible?. European Journal of Pharmaceutics and Biopharmaceutics, 172, 112-122. https://doi.org/10.1016/j.ejpb.2022.02.004

• Journal Article Type: Article
• Acceptance Date: Feb 5, 2022
• Online Publication Date: Feb 17, 2022
• Publication Date: Mar 1, 2022
• Deposit Date: May 19, 2022
• Publicly Available Date: May 19, 2022
• Journal: European Journal of Pharmaceutics and Biopharmaceutics
• Print ISSN: 0939-6411
• Electronic ISSN: 1873-3441
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 172
• Pages: 112-122
• DOI: https://doi.org/10.1016/j.ejpb.2022.02.004
• Keywords: Pharmaceutical Science; General Medicine; Biotechnology
• Public URL: https://nottingham-repository.worktribe.com/output/7508912
• Publisher URL: https://www.sciencedirect.com/science/article/pii/S093964112200025X?via%3Dihub